Mainz Biomed (NASDAQ:MYNZ – Free Report)’s stock is going to reverse split on Tuesday, December 3rd. The 1-40 reverse split was announced on Friday, November 29th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, December 2nd.
Mainz Biomed Stock Performance
Shares of MYNZ traded down $0.04 during trading hours on Friday, hitting $0.22. The stock had a trading volume of 7,094,717 shares, compared to its average volume of 1,350,238. Mainz Biomed has a 12 month low of $0.19 and a 12 month high of $1.79. The stock has a fifty day moving average price of $0.26 and a 200 day moving average price of $0.39.
Analysts Set New Price Targets
Separately, HC Wainwright lowered Mainz Biomed from a “buy” rating to a “neutral” rating in a report on Monday.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Featured Stories
- Five stocks we like better than Mainz Biomed
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- What Are Dividend Challengers?
- 3 Penny Stocks Ready to Break Out in 2025
- Comparing and Trading High PE Ratio Stocks
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.JPG?v=20240830132618&h=45&w=95&zc=2){kind=logo}